Characteristics | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age | 1.01 (0.99–1.02) | 0.26 |  |  |
Male | 1.09 (0.70–1.70) | 0.70 |  |  |
Nosocomial or healthcare-associated bacteremia | 0.85 (0.48–1.51) | 0.58 |  |  |
Charlson index | 0.94 (0.85–1.03) | 0.20 | 0.98 (0.89–0.96) | 0.74 |
Hematological malignancy | 1.03 (0.53–2.00) | 0.93 |  |  |
Solid malignancy | 0.95 (0.60–1.49) | 0.82 |  |  |
Transplantation | 0.65 (0.33–1.30) | 0.23 |  |  |
Hemodialysis | 0.43 (0.16–1.19) | 0.10 |  |  |
Diabetes | 1.07 (0.65–1.76) | 0.79 |  |  |
Cardiac disease | 0.86 (0.54–1.37) | 0.52 |  |  |
Chronic lung disease | 0.99 (0.56–1.73) | 0.96 |  |  |
Liver disease | 0.69 (0.40–1.19) | 0.18 |  |  |
Pancreatobilliary disease | 0.93 (0.55–1.60) | 0.81 |  |  |
Chronic kidney disease | 0.95 (0.60–1.50) | 0.83 |  |  |
Connective tissue disease | 0.87 (0.42–1.81) | 0.72 |  |  |
Intravascular catheter | 0.60 (0.39–0.93) | 0.02 |  |  |
Urinary catheter | 0.69 (0.42–1.13) | 0.14 |  |  |
Mechanical ventilation | 0.50 (0.20–1.24) | 0.13 |  |  |
Other artificial devices | 0.74 (0.46–1.17) | 0.20 |  |  |
Use of all immunosuppressive therapy within 30 days | 0.90 (0.58–1.39) | 0.64 |  |  |
Neutropenia | 0.88 (0.47–1.66) | 0.70 |  |  |
Previous surgery within 30 days | 0.69 (0.37–1.27) | 0.23 |  |  |
Invasive procedure within 30 days | 0.63 (0.39–1.04) | 0.07 |  |  |
Source of infection | ||||
 Urinary tract infection | 1.17 (0.71–1.94) | 0.54 |  |  |
 Intraabdominal infection | 0.72 (0.42–1.23) | 0.23 |  |  |
 Pneumonia | 0.74 (0.23–2.36) | 0.62 |  |  |
 Primary bacteremia | 0.85 (0.53–1.36) | 0.50 |  |  |
 SOFA score | 0.86 (0.79–0.94) | <0.01 | 0.88 (0.80–0.96) | <0.01 |
Empirical therapy | ||||
 Carbapenems | 0.41 (0.22–0.75) | <0.01 |  |  |
 Third-generation cephalosporinsa | 2.54 (1.56–4.14) | <0.01 | 2.13 (1.30–3.50) | <0.01 |
 Other cephems | 1.32 (0.83–2.10) | 0.25 |  |  |
 β-lactam/β-lactamase inhibitors | 0.66 (0.39–1.11) | 0.12 |  |  |
 Appropriate empirical therapy | 1.43 (0.79–2.58) | 0.24 |  |  |
 CTXNS-En bacteremia | 0.64 (0.39–1.03) | 0.07 | 0.73 (0.45–1.19) | 0.20 |